Phathom Pharmaceuticals, Inc. ROE

ROE of PHAT for past 10 years: annual, quarterly and twelve month trailing (TTM) including ROE growth rates and interactive chart. ROE is expressed as a percentage and can be calculated for any company if net income and equity are both positive numbers. Net income is calculated before dividends paid to common shareholders and after dividends to preferred shareholders and interest to lenders. A company with average equity of $10 million and earnings of $2 milion will have a ROE of 20%.


Highlights and Quick Summary

  • Annual ROE for 2020 was -61.14% (a -72.84% decrease from previous year)
  • Annual ROE for 2019 was -225.11% (a -Infinity% decrease from previous year)
  • Twelve month ROE ending September 29, 2021 was -124.51% (a 25.34% increase compared to previous quarter)
  • Twelve month trailing ROE increased by 103.65% year-over-year
Trailing ROE for the last four month:
29 Sep '21 29 Jun '21 30 Mar '21 30 Dec '20
-124.51% -99.34% -77.08% -61.14%
Visit stockrow.com/PHAT for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical ROE of Phathom Pharmaceuticals, Inc.

Most recent ROEof PHAT including historical data for past 10 years.

Interactive Chart of ROE of Phathom Pharmaceuticals, Inc.

Phathom Pharmaceuticals, Inc. ROE for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 -61.14%
2019 -225.11%
2018 0.0%

Business Profile of Phathom Pharmaceuticals, Inc.

Sector: Healthcare
Industry: Biotechnology
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.